🚀 VC round data is live in beta, check it out!
Basilea Pharmaceutica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Basilea Pharmaceutica and similar public comparables like Bright Minds Biosciences, Arbutus Biopharma, Sana Biotechnology, Theravance and more.
Basilea Pharmaceutica Overview
About Basilea Pharmaceutica
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
Founded
2000
HQ
Employees
189
Website
Sectors
Financials (LTM)
EV
$750M
Basilea Pharmaceutica Financials
Basilea Pharmaceutica reported last 12-month revenue of $306M and EBITDA of $67M.
In the same LTM period, Basilea Pharmaceutica generated $257M in gross profit, $67M in EBITDA, and $57M in net income.
Revenue (LTM)
Basilea Pharmaceutica P&L
In the most recent fiscal year, Basilea Pharmaceutica reported revenue of $300M and EBITDA of $65M.
Basilea Pharmaceutica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $306M | XXX | $300M | XXX | XXX | XXX |
| Gross Profit | $257M | XXX | $244M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $67M | XXX | $65M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $57M | XXX | $52M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Basilea Pharmaceutica Stock Performance
Basilea Pharmaceutica has current market cap of $839M, and enterprise value of $750M.
Market Cap Evolution
Basilea Pharmaceutica's stock price is $68.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $750M | $839M | 1.4% | XXX | XXX | XXX | $4.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBasilea Pharmaceutica Valuation Multiples
Basilea Pharmaceutica trades at 2.4x EV/Revenue multiple, and 11.1x EV/EBITDA.
EV / Revenue (LTM)
Basilea Pharmaceutica Financial Valuation Multiples
As of April 10, 2026, Basilea Pharmaceutica has market cap of $839M and EV of $750M.
Equity research analysts estimate Basilea Pharmaceutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Basilea Pharmaceutica has a P/E ratio of 14.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $839M | XXX | $839M | XXX | XXX | XXX |
| EV (current) | $750M | XXX | $750M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBIT | 10.5x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | 14.6x | XXX | 16.2x | XXX | XXX | XXX |
| EV/FCF | 35.6x | XXX | 10.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Basilea Pharmaceutica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Basilea Pharmaceutica Margins & Growth Rates
Basilea Pharmaceutica's revenue in the last 12 month grew by 6%.
Basilea Pharmaceutica's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.9M for the same period.
Basilea Pharmaceutica's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Basilea Pharmaceutica's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Basilea Pharmaceutica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | 44% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 15% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 46% | XXX | 46% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Basilea Pharmaceutica Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bright Minds Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Arbutus Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sana Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Theravance | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Basilea Pharmaceutica M&A Activity
Basilea Pharmaceutica acquired XXX companies to date.
Last acquisition by Basilea Pharmaceutica was on XXXXXXXX, XXXXX. Basilea Pharmaceutica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Basilea Pharmaceutica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBasilea Pharmaceutica Investment Activity
Basilea Pharmaceutica invested in XXX companies to date.
Basilea Pharmaceutica made its latest investment on XXXXXXXX, XXXXX. Basilea Pharmaceutica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Basilea Pharmaceutica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Basilea Pharmaceutica
| When was Basilea Pharmaceutica founded? | Basilea Pharmaceutica was founded in 2000. |
| Where is Basilea Pharmaceutica headquartered? | Basilea Pharmaceutica is headquartered in Switzerland. |
| How many employees does Basilea Pharmaceutica have? | As of today, Basilea Pharmaceutica has over 189 employees. |
| Is Basilea Pharmaceutica publicly listed? | Yes, Basilea Pharmaceutica is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Basilea Pharmaceutica? | Basilea Pharmaceutica trades under BSLN ticker. |
| When did Basilea Pharmaceutica go public? | Basilea Pharmaceutica went public in 2004. |
| Who are competitors of Basilea Pharmaceutica? | Basilea Pharmaceutica main competitors are Bright Minds Biosciences, Arbutus Biopharma, Sana Biotechnology, Theravance. |
| What is the current market cap of Basilea Pharmaceutica? | Basilea Pharmaceutica's current market cap is $839M. |
| What is the current revenue of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months revenue is $306M. |
| What is the current revenue growth of Basilea Pharmaceutica? | Basilea Pharmaceutica revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Basilea Pharmaceutica? | Current revenue multiple of Basilea Pharmaceutica is 2.4x. |
| Is Basilea Pharmaceutica profitable? | Yes, Basilea Pharmaceutica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months EBITDA is $67M. |
| What is Basilea Pharmaceutica's EBITDA margin? | Basilea Pharmaceutica's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Basilea Pharmaceutica? | Current EBITDA multiple of Basilea Pharmaceutica is 11.1x. |
| What is the current FCF of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12 months FCF is $21M. |
| What is Basilea Pharmaceutica's FCF margin? | Basilea Pharmaceutica's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Basilea Pharmaceutica? | Current FCF multiple of Basilea Pharmaceutica is 35.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.